Hemostemix Inc. (CVE:HEM – Get Free Report) was up 25% during mid-day trading on Thursday . The stock traded as high as C$0.15 and last traded at C$0.15. Approximately 411,648 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 461,633 shares. The stock had previously closed at C$0.12.
Hemostemix Stock Performance
The stock has a market capitalization of C$21.86 million, a price-to-earnings ratio of -4.37 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The firm has a 50-day moving average of C$0.10 and a 200-day moving average of C$0.14.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- CD Calculator: Certificate of Deposit Calculator
- Wall Street Sees More Upside for Dell and HPE
- What is a SEC Filing?
- Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May
- What is a Stock Market Index and How Do You Use Them?
- GameStop Turns a Profit, But Core Business Keeps Shrinking
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
